Search clinical trials for: intermediate stage

Total 16849 results

Peking University People's Hospital

Not yet recruiting

Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

Carcinoma, Endometrioid | Fertility Preservation
Sun Yat-sen University

Recruiting

Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria) (BEST)

Hepatocellular Carcinoma

China
Sun Yat-sen University
First People's Hospital of Foshan; The First Affiliated Hospital, Guangzhou... and other collaborators

Recruiting

Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC (HAIC)

Hepatocellular Carcinoma | Chemotherapy Effect | Chemotherapeutic Toxicity

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Intermediate Grade Prostate Cancer

Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8

United States
Rutgers, The State University of New Jersey

Recruiting

One-month Latent Tuberculosis Treatment for Renal Transplant Candidates

End Stage Renal Disease | Latent Tuberculosis | Renal Transplant Candidate for Right Kidney | Renal Transplant Candidate for Left Kidney

United States
Zhongda Hospital

Recruiting

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC (CHANCE2202)

Hepatocellular Carcinoma

China
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

Hepatocellular Carcinoma

China
Institut de la Macula y la Retina
Igen BioLab SLU

Recruiting

Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration. (REVERS)

AMD | Drusen Stage Macular Degeneration | Soft Drusen | Reticular Pseudodrusen | Drusen (Degenerative) of Macula, Bilateral

Spain
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Hepatocellular Carcinoma

Austria, Germany, Spain, Japan, Italy, France
Translational Research in Oncology
Bayer

Recruiting

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 (REPLACE)

Carcinoma, Hepatocellular

Korea, Republic of, United States, Taiwan, Spain, Japan, France, Georgia, Belgium, Germany, Turkey, Italy, Hong Kong, Serbia
Institut für Klinische Krebsforschung IKF GmbH...
Hannover Medical School; AstraZeneca

Recruiting

Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

HCC | Hepatocellular Carcinoma Non-resectable

Germany
Ruijin Hospital

Recruiting

Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer

Breast Cancer

China
Fudan University

Not yet recruiting

The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

Hepatocellular Carcinoma
The Clatterbridge Cancer Centre NHS Foundation...

Recruiting

Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC (TACE-3)

Hepatocellular Carcinoma

United Kingdom
The Netherlands Cancer Institute
Bristol-Myers Squibb; Eli Lilly and Company; Bayer; GlaxoSmithKline; Merck Sharp... and other collaborators

Recruiting

The Drug Rediscovery Protocol (DRUP Trial) (DRUP)

Cancer | Neoplasm | Tumors | Neoplasia

Netherlands
Mayo Clinic

Recruiting

Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors

Prostate Cancer | Prostate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8

United States
Ming Zhao

Recruiting

TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma

Hepatocellular Carcinoma | Chemoembolization, Therapeutic | Ablation Techniques, RFA

China
Razor Genomics
Encore Clinical

Recruiting

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States, France, Germany
UNICANCER
Ipsen

Active, not recruiting

Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

Prostate Cancer

France
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Stage I Uterine Corpus Cancer AJCC v8 | Stage II Uterine Corpus Cancer AJCC v8

United States, Puerto Rico
Fudan University

Completed

cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria

Hepatocellular Carcinoma

China
Moscow City Oncology Hospital No. 62

Completed

[SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer (SENTRY)

Endometrial Neoplasms | Endometrial Cancer | Sentinel Lymph Node | Endometrial Endometrioid Adenocarcinoma | Endometrial Adenocarcinoma | Hysterectomy | Endometrial Cancer Stage I | Laparoscopic Hysterectomy | Endometrial Cancer Stage II

Russian Federation
Celgene

Completed

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY)

Leukemia, Myeloid | Isocitrate Dehydrogenase

United States, Canada, China, Czechia, France, Germany, Italy, United Kingdom, Australia, Austria, Brazil, Denmark, Korea, Republic of, Russian Federation, Spain, Taiwan, Turkey, Belgium
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
Bristol-Myers Squibb

Terminated

A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer (CheckMate 74W)

Cancer, Hepatocellular

China, United States, Germany, Australia, Italy, Austria, Belgium, Czechia, France, Hong Kong, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Taiwan, Canada
Andrei Iagaru

Completed

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate Adenocarcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca

Active, not recruiting

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Hepatocellular Carcinoma | Intermediate Stage of Hepatocellular Carcinoma

United States
Centre Oscar Lambret
Institut National de la Santé Et de la Recherche Médicale, France; National... and other collaborators

Active, not recruiting

Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. (SENTIRAD)

Endometrial Carcinoma

France
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Sarcoma

United States
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | Transformed Non-Hodgkin Lymphoma | Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage... and other conditions

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Astellas Pharma Inc; Medivation, Inc.

Active, not recruiting

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Recurrent Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIB Prostate Cancer

United States
University of Florida
National Institute of Nursing Research (NINR)

Completed

Early Initiation of Milk Expression in Mothers of Very Low Birth Weight Infants

Breast Milk Expression

United States
MagForce USA

Terminated

Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Prostate Cancer

United States
AIO-Studien-gGmbH
Bristol-Myers Squibb

Completed

Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma (IMMUTACE)

Carcinoma, Hepatocellular | Hepatocellular Cancer | Hepatic Carcinoma

Germany
Eastern Hepatobiliary Surgery Hospital

Active, not recruiting

Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Jonsson Comprehensive Cancer Center

Completed

68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery

Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States
Danish Gynecological Cancer Group
European Organisation for Research and Treatment of Cancer - EORTC; Belgian... and other collaborators

Active, not recruiting

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Endometrial Cancer

Denmark
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer (PALS)

Prostate Adenocarcinoma | Stage I Prostate Cancer AJCC V7 | Stage IIA Prostate Cancer AJCC v7

United States
University Hospital, Ghent

Terminated

Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC) (TRACE)

Hepatocellular Carcinoma

Belgium
Teclison Ltd.

Suspended

TATE Versus TACE in Intermediate Stage HCC (TATE)

Carcinoma, Hepatocellular

United States
Cara Therapeutics, Inc.

Approved for marketing

Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin

Uremic Pruritus
West China Hospital

Completed

Early Evaluation of Chemosensitivity for Low/Intermediated-risk Mid-low Stage II/III Rectal Cancer

Rectal Cancer

China
Benha University
Beni-Suef University

Completed

RFA for Treatment of Intermediate Stage HCC

Hepatocellular Carcinoma

Egypt
UNICANCER
Pfizer; NanoString Technologies, Inc.

Completed

Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women (NeoPAL)

Neoadjuvant Operable Breast Cancer

France
Andrei Iagaru
National Cancer Institute (NCI)

Completed

68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma

United States
Institute of Cancer Research, United Kingdom
Merck Sharp & Dohme LLC; National Institute for Health Research Biomedical...

Active, not recruiting

A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients (c-TRAK-TN)

Triple Negative Breast Cancer

United Kingdom
Ankara Training and Research Hospital

Completed

Efficacy and Safety of Obturator Nerve Block During Transurethral Resection on Non-muscle Invasive Intermediate and High Risk Lateral Wall Bladder Tumours

Bladder Cancer Stage 0 | Bladder Cancer Stage I

Turkey
German Breast Group
Celgene Corporation; Amgen

Completed

Denosumab as an add-on Neoadjuvant Treatment (GeparX) (GeparX)

Inflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III

Germany
Jonsson Comprehensive Cancer Center

Withdrawn

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

Prostate Adenocarcinoma | Stage II Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States

Search clinical trials for: intermediate stage

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations